| MNK (MNK) | |||
|---|---|---|---|
| 0.3402 -0.06 (-14.97%) | 08-25 16:00 | ||
| Open: | 0.4 | Pre. Close: | 0.4001 |
| High: | 0.4102 | Low: | 0.3 |
| Volume: | 543,145 | Market Cap: | 5(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 0.43 -10000000000 One year: 0.48 -10000000000 |
| Support: | Support1: 0.30 -10000000000 Support2: 0.25 -10000000000 |
| Resistance: | Resistance1: 0.37 -10000000000 Resistance2: 0.41 -10000000000 |
| Pivot: | -10000000000 |
| Moving Averages: | MA(5): MA(20): MA(100): MA(250): |
| MACD: | MACD(12,26): -10000000000.00 -10000000000 Signal(12,26,9): -10000000000.00 -10000000000 |
| %K %D: | %K(14,3): -10000000000.00 -10000000000 %D(3): -10000000000.00 -10000000000 |
| RSI: | RSI(14): -10000000000.00 -10000000000 |
| 52-Week: | High: 16 Low: 0.3 Change(%): |
| Average Vol(K): | 3-Month: -10000000000 10-Days: -10000000000 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MNK ] has closed Bollinger Bands are 0% narrower than normal. |
| Company profile |
|---|
| Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: American Stock Exchange | |
| Sector: Healthcare | |
| Industry: Drug Manufacturers - Specialty & Generic | |
| Shares Out. (M) | |
| Shares Float (M) | |
| % Held by Insiders | |
| % Held by Institutions | |
| Shares Short (K) | |
| Shares Short Prior Month (K) | |
| Stock Financials | |
|---|---|
| EPS | |
| Book Value (p.s.) | |
| Profit Margin | |
| Operating Margin | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) | |
| Qtrly Rev. Growth | |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | |
| Levered Free Cash Flow (M) | |
| Stock Valuation | |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow | |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
